Qiagen

QIAGEN N.V.
Company typePublic (Naamloze vennootschap)
ISINNL0015001WM6
IndustryBiotechnology
FoundedNovember 29, 1984; 39 years ago (1984-11-29)
Founders
  • Metin Colpan
  • Karsten Henco
  • Jürgen Schumacher
Headquarters
  • Venlo, Netherlands (corporate)
  • Hilden, Germany (operational)
Key people
  • Thierry Bernard (CEO)
  • Lawrence A. Rosen (chairman of supervisory board)
RevenueDecrease US$1.97 billion (2023)
Decrease US$410 million (2023)
Decrease US$341 million (2023)
Total assetsDecrease US$6.12 billion (2023)
Total equityIncrease US$3.81 billion (2023)
Number of employees
5,967 (2023)
Websiteqiagen.com
Footnotes / references
[1][2]

QIAGEN N.V. is a German-founded multinational provider of sample and assay technologies for molecular diagnostics, applied testing, academic research, and pharmaceutical research. The company operates in more than 35 offices in over 25 countries. QIAGEN N.V., the global corporate headquarter of the QIAGEN group, is located in Venlo, The Netherlands. The main operative headquarters are located in Hilden, Germany.[3] European, American, Chinese, and Asian-Pacific regional headquarters are located respectively in respectively Hilden, Germany; Germantown, Maryland, United States; Shanghai, China; and Singapore.[4] QIAGEN's shares are listed at the NYSE (using ticker QGEN) and at the Frankfurt Stock Exchange in the Prime Standard (using ticker QIA). Thierry Bernard is the company's Chief Executive Officer (CEO).

  1. ^ "2023 Annual Report (Form 20-F)". US Securities and Exchange Commission. 11 March 2024.
  2. ^ "Supervisory Board". Archived from the original on 11 July 2017.
  3. ^ "Our global presence | QIAGEN". www.qiagen.com (in German). Retrieved 22 February 2024.
  4. ^ "Company Presentation" (PDF). corporate.qiagen.com. 20 February 2024. Retrieved 20 February 2024.